We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson ...
Johnson & Johnson posts strong Q3 2025 with robust sales, new acquisitions, and FDA approvals expanding oncology and CNS ...
The Bulldogs dominated the glass and in the paint, led by Michael Ajayi, in their tournament opener against the Gamecocks.
Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide ...
Guselkumab (Tremfya; Johnson & Johnson) continued to reduce signs and symptoms of active psoriatic arthritis (PsA) and ...
A strong year for initial public offerings on Wall Street has fizzled out due to the government shutdown and a cautious turn ...
Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if ...
2don MSN
US filings for jobless benefits remained in historically healthy range during government shutdown
New U.S. jobless claim applications fell last week, remaining within the healthy range of recent years, according to the ...
Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...
With phase I/II data in hand, Taiho Pharmaceutical Co. Ltd. and Cullinan Therapeutics Inc. began filing a rolling NDA to the U.S. FDA for accelerated approval of zipalertinib to treat patients with ...
Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA (lumateperone) as an adjunctive therapy with antidepressants for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback